Transcript
Page 1: Prospera Transplant assessment test · 2019-09-03 · Prospera : Transplant assessment test Broad, highly accurate assessment of active rejection DIVERSE COHORT KEY ADVANTAGES 107

Simpler and less invasive than biopsy; no donor genotyping required

Suitable for most renal allograft patients across ethnicities

More sensitive and speci�c for clinical and subclinical active rejection than serum creatinine2

Up to 5x more reduction in variability than that of a competitive dd-cfDNA assay1,3

Analytically & clinically validated to be:

266

9.2%

4.5%

NO

Prospera2 ExistingCommercial Assay3

Prospera : Transplant assessment testBroad, highly accurate assessment of active rejection

DIVERSE COHORT

KEY ADVANTAGES

107

0.74

Prospera1 ExistingCommercial Assay4

More SNPs targeted and analyzed2

Precision within run 5x better2

Coef�cient of Variation

Precision across runs 2.3x better2

Coef�cient of Variation

Only assay with evaluatedperformance in related and unrelated donors

T-cell mediated rejection IA/IB/IIBAntibody-mediated rejectionC4d-positive antibody-mediated rejectionAcute rejectionChronic active rejectionMixed rejection

••••••

Largest published renal transplant dd-cfDNA validation study1

Highest reported overall accuracy1

AUC

First, only test to identify subclinical rejection1

Sensitivity

Highest reported performance to assess T-cell mediated rejection1

Sensitivity

Broad distribution of rejection types2

Hispanic / Latino (n=50)Caucasian (n=74)African American (n=31)Asian (n=31)

Variety of ethnic and racial demographics2

CAP accredited, ISO 13485, and CLIA certi�ed. © 2019 Natera, Inc. All Rights Reserved.PRO_ESOT_BoothPoster_20190903_NAT-8019995

1 Sigdel, et al. J Clin Med. 2019;8(1):19.2 Altuğ, et al. Transplantation, 20193 Grskovic, et al. J Mol Diagn. 2016;18(6):890-902.4 Bloom RD, et al. J Am Soc Nephrol. 2017 Jul;28(7):2221-2232.

PERFORMANCE COMPARISON

Of 100 active rejection cases, the number of patients who would be missed, and told they are normal*

*Using a 1% dd-cfDNA threshold

NA

27%

ANALYTICAL VALIDATION CLINICAL VALIDATION

217

0.87

92%

100%

~ 13,000

1.85%

1.9%

YES

Prospera1 First-generationdd-cfDNA4

Sensitivity Sensitivity89% 59%

11/100 41/100

September 03, 2019 Size: 36”W x 24”H Artwork at 100% 1/4” bleed included all around Poster print on foam board TRIM

Top Related